BuSpar
(Buspirone)ApprovedSmall molecule
Bristol-Myers SquibbBuspirone is used to treat anxiety disorders and help reduce feelings of worry and nervousness. It works by affecting certain chemicals in the brain that control mood and anxiety.[2] BuSpar is currently approved and in use across 27 indications[4].[1]
BuSpar is one of 651 small molecule programs targeting Gastroparesis. It is currently in Approved.
27
Indications
48
Total Trials
6
Active Trials
650
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 27 indications
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1BuSpar
Bristol-Myers SquibbApproved
Activase
RochePreclinical
Zometa
PfizerPreclinical
Folvite
Eli LillyPreclinical
Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Pradaxa
Boehringer IngelheimPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment5 trials
Autism Spectrum Disorder4 trials
Cocaine Dependence2 trials
Brain Injury2 trials
34 more indications
Sleep Apnea1 trial
Function1 trial
Amantadine1 trial
Stroke1 trial
Neuromodulation1 trial
Acute Effects of Pharmacological Neuromodulation on Leg Motor Activity in Patients With SCI Treated With EES
Completed·—·Phase 1·NCT04052776·3 enrolled
Generalized Anxiety Disorder1 trial
Clinical Trial1 trial
Vertigo1 trial
Age1 trial
Epilepsy1 trial
Buspirone Therapy for Localized Epilepsy
Terminated·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT01496612·9 enrolled
Major Depression1 trial
Concentration1 trial
Effectiveness1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Sep 29, 1986
BUSPAR
NDA NDA018731
Dec 20, 2000
BUSPAR
NDA NDA021190
Sources
References
- [1]
- [2]MedlinePlus Drug Information — BuSpar drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Buspirone. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Serotonin 1a (5-Ht1a) Receptor Partial Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company